Physician profile
Robert Macdonald
NPI 1528035425
$1,583.60
in general payments reported to CMS, 2019-2025
24 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $219 · 2021: $20.65 · 2022: $156 · 2023: $154 · 2024: $223 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $314.13 | 2019-2025 | |
| Abbott Laboratories | $239.27 | 2019-2024 | Navitor, Perclose Prostyle |
| Boston Scientific Corporation | $156.28 | 2019-2024 | Opticross, Wolverine Coronary Cutting Balloon |
| Nuwellis, INC. | $154.80 | 2019 | |
| Abiomed | $103.51 | 2025 | |
| Amgen INC. | $80.24 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $68.29 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $55.99 | 2019-2022 | |
| Inari Medical, INC. | $44.98 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Gilead Sciences, INC. | $40.76 | 2022 | |
| Stryker Corporation | $40.64 | 2025 | Flowtriever |
| Cvrx, INC. | $38.56 | 2024-2025 | Barostim Neo System |
| Pfizer INC. | $34.96 | 2019-2020 | |
| Amarin Pharma, INC. | $27.70 | 2019 | |
| Atricure, INC. | $26.56 | 2022-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.65 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.37 | 2023 | Camzyos |
| Allergan, INC. | $18.34 | 2020 | |
| Mylan Specialty L.P. | $18.27 | 2019 | |
| Esperion Therapeutics, INC. | $17.23 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.89 | 2023 | Lifevest |
| Medtronic Vascular, INC. | $14.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.